Michael Grissinger - 01 Jan 2024 Form 3 Insider Report for Akari Therapeutics Plc (AKTX)

Role
Director
Signature
/s/ Rachelle Jacques, as Attorney-in-Fact for Michael Grissinger
Issuer symbol
AKTX
Transactions as of
01 Jan 2024
Net transactions value
$0
Form type
3
Filing time
02 Jan 2024, 18:41:51 UTC
Previous filing
24 Aug 2023
Next filing
21 Jun 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding AKTX Ordinary Shares, par value $0.0001 per share 20,000,000 01 Jan 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding AKTX Stock Option (Right to Buy) 01 Jan 2024 Ordinary Shares, par value $0.0001 per share 1,300,000 $0.0347 Direct F1
holding AKTX Stock Option (Right to Buy) 01 Jan 2024 Ordinary Shares, par value $0.0001 per share 1,300,000 $0.0208 Direct
holding AKTX Stock Option (Right to Buy) 01 Jan 2024 Ordinary Shares, par value $0.0001 per share 1,300,000 $0.0207 Direct
holding AKTX Stock Option (Right to Buy) 01 Jan 2024 Ordinary Shares, par value $0.0001 per share 1,300,000 $0.0218 Direct
holding AKTX Stock Option (Right to Buy) 01 Jan 2024 Ordinary Shares, par value $0.0001 per share 1,300,000 $0.0173 Direct
holding AKTX Stock Option (Right to Buy) 01 Jan 2024 Ordinary Shares, par value $0.0001 per share 1,300,000 $0.0100 Direct
holding AKTX Stock Option (Right to Buy) 01 Jan 2024 Ordinary Shares, par value $0.0001 per share 3,700,000 $0.004800 Direct
holding AKTX Stock Option (Right to Buy) 01 Jan 2024 Ordinary Shares, par value $0.0001 per share 5,000,000 $0.001700 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Non-qualified stock option granted under the Issuer's 2014 Equity Incentive Plan. The stock option vested and became exercisable in four equal installments of twenty-five percent (25%), with the with the first installment vesting on January 23, 2019 and an additional 25% vesting on each annual anniversary of the vesting date thereafter.
F2 Non-qualified stock option granted under the Issuer's 2023 Equity Incentive Plan. One-hundred percent (100%) of the stock option vests and becomes exercisable on the date of the Issuer's 2024 Annual General Meeting.

Remarks:

See Exhibit 24.1 - Power of Attorney